keyword
MENU ▼
Read by QxMD icon Read
search

Dimethyl fumarate

keyword
https://www.readbyqxmd.com/read/29336841/economic-impact-of-the-new-oral-treatments-for-multiple-sclerosis
#1
L Álvarez Ayuso, B Rodríguez Marrodán, M R Blasco Quílez, J A García-Merino, A Sánchez Guerrero
INTRODUCTION: Multiple sclerosis (MS) is a chronic disease affecting the central nervous system and is characterised by inflammation, demyelination, gliosis, and axonal damage. The introduction of dimethyl fumarate and teriflunomide has led to an increase in the number of alternative first-line therapies for MS. The objective of this study was to evaluate the economic impact of the incorporation of new oral therapies at the reference unit (CSUR) at Hospital Universitario Puerta de Hierro Majadahonda...
January 11, 2018: Neurología: Publicación Oficial de la Sociedad Española de Neurología
https://www.readbyqxmd.com/read/29326286/correction-dimethyl-fumarate-for-psoriasis
#2
(no author information available yet)
No abstract text is available yet for this article.
January 11, 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29317954/a-multiple-treatment-comparison-of-eleven-disease-modifying-drugs-used-for-multiple-sclerosis
#3
Vida Hamidi, Elisabeth Couto, Tove Ringerike, Marianne Klemp
Background: Several disease-modifying drug therapies are available for the treatment of multiple sclerosis (MS). To ensure the most appropriate MS management, we assessed the effectiveness and cost-effectiveness of the disease-modifying medicines used for MS. Methods: We conducted a systematic review including 11 disease-modifying drugs used for treatment of adult patients diagnosed with relapsing-remitting MS. We performed a network meta-analysis using both direct and indirect evidence...
February 2018: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/29316038/effect-of-dimethyl-fumarate-on-gray-and-white-matter-pathology-in-subjects-with-relapsing-multiple-sclerosis-a-longitudinal-study
#4
Robert Zivadinov, Jesper Hagemeier, Niels Bergsland, Eleonora Tavazzi, Bianca Weinstock-Guttman
BACKGROUND: Dimethyl fumarate (DMF) is an oral treatment for relapsing remitting multiple sclerosis (RRMS) with anti-inflammatory and possible neuroprotective properties. Its effect on white matter (WM) and gray matter (GM) pathology is still not fully understood. OBJECTIVE: To characterize the effect of DMF on normal appearing WM (NAWM) and thalamic pathology longitudinally. METHODS: In this observational, longitudinal, 24-month MRI study, 75 RRMS treated with DMF and 40 age- and sex- matched healthy individuals (HIs) were enrolled...
January 5, 2018: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/29304497/predictors-of-hematological-abnormalities-in-multiple-sclerosis-patients-treated-with-fingolimod-and-dimethyl-fumarate-and-impact-of-treatment-switch-on-lymphocyte-and-leukocyte-count
#5
M Baharnoori, C T Gonzalez, A Chua, C Diaz-Cruz, B C Healy, J Stankiewicz, H L Weiner, T Chitnis
BACKGROUND: There is limited data regarding the predictors of hematological abnormalities in multiple sclerosis (MS) patients treated with dimethyl fumarate (DMF) or fingolimod (FNG), and the impact of treatment switch on lymphocyte and leukocyte count METHODS: We identified 405 patients on DMF and 300 patients on FNG (treatment duration: at least 12 month) within a large prospective study of MS patients conducted at the Partners MS Center, Brigham and Women's Hospital (CLIMB study) between Jan 2011 to Feb 2016...
December 14, 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29296636/characterization-of-lymphopenia-in-patients-with-ms-treated-with-dimethyl-fumarate-and-fingolimod
#6
Maryam Nakhaei-Nejad, David Barilla, Chieh-Hsin Lee, Gregg Blevins, Fabrizio Giuliani
Objective: Lymphopenia is a common occurrence of disease-modifying therapies (DMTs) for relapsing-remitting MS (RRMS). The aim of this study was to dissect the prevalence of various lymphocyte subsets in patients with RRMS treated with 2 DMTs commonly associated with lymphopenia, dimethyl fumarate (DMF), and fingolimod (FTY). Methods: Multicolor flow cytometry and multiplex assays were used to identify up to 50 lymphocyte subpopulations and to examine the expression of multiple cytokines in selected patients...
March 2018: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/29237700/dimethyl-fumarate-for-psoriasis
#7
(no author information available yet)
Dimethyl fumarate (Skilarence - Almirall) was licensed by the European Medicines Agency in June 2017 for the treatment of moderate to severe plaque psoriasis in adults in need of systemic therapy.1 An unlicensed formulation of dimethyl fumarate has been used in the UK for the management of psoriasis for several years. Here, we consider the evidence for the new product and how it fits with current strategies for the management of adults with psoriasis.
December 2017: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29236231/dimethyl-fumarate-a-review-in-moderate-to-severe-plaque-psoriasis
#8
Hannah A Blair
Fumaric acid esters (FAEs) have been used in the treatment of psoriasis in some European countries for over 20 years, and are recommended in the European guidelines for the management of moderate to severe plaque psoriasis. Dimethyl fumarate (Skilarence®; hereafter referred to as DMF) is an orally administered FAE indicated for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy; unlike other available FAEs, it is not formulated in combination with monoethyl fumarate salts...
December 13, 2017: Drugs
https://www.readbyqxmd.com/read/29229891/cost-effectiveness-of-oral-agents-in-relapsing-remitting-multiple-sclerosis-compared-to-interferon-based-therapy-in-saudi-arabia
#9
Mai F Alsaqa'aby, Varun Vaidya, Noura Khreis, Thamer Al Khairallah, Ahmed H Al-Jedai
BACKGROUND: Promising clinical and humanistic outcomes are associated with the use of new oral agents in the treatment of relapsing-remitting multiple sclerosis (RRMS). This is the first cost-effectiveness study comparing these medications in Saudi Arabia. OBJECTIVES: We aimed to compare the cost-effectiveness of fingolimod, teriflunomide, dimethyl fumarate, and interferon (IFN)-b1a products (Avonex and Rebif) as first-line therapies in the treatment of patients with RRMS from a Saudi payer perspective...
November 2017: Annals of Saudi Medicine
https://www.readbyqxmd.com/read/29218681/management-strategies-to-facilitate-optimal-outcomes-for-patients-treated-with-delayed-release-dimethyl-fumarate
#10
Lori Mayer, Mary Kay Fink, Carrie Sammarco, Lisa Laing
Delayed-release dimethyl fumarate is an oral disease-modifying therapy that has demonstrated significant efficacy in adults with relapsing-remitting multiple sclerosis. Incidences of flushing and gastrointestinal adverse events are common in the first month after delayed-release dimethyl fumarate initiation. Our objective was to propose mitigation strategies for adverse events related to initiation of delayed-release dimethyl fumarate in the treatment of patients with multiple sclerosis. Studies of individually developed mitigation strategies and chart reviews were evaluated...
December 7, 2017: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/29209333/inhibition-of-acute-graft-versus-host-disease-with-retention-of-graft-versus-tumor-effects-by-dimethyl-fumarate
#11
Jingjing Han, Shoubao Ma, Huanle Gong, Shuangzhu Liu, Lei Lei, Bo Hu, Yang Xu, Haiyan Liu, Depei Wu
Acute graft-versus-host disease (aGVHD) remains a clinical challenge and a major source of morbidity and mortality following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Dimethyl fumarate (DMF), an activator of Nrf2, has been shown to have anti-inflammatory and immunomodulatory properties without significant immunosuppression. We therefore hypothesized that DMF could be potentially harnessed for the treatment of aGVHD with retention of graft-versus-tumor effect. In this study, we showed that DMF significantly inhibited alloreactive T cell responses in vitro in mixed lymphocyte reaction assay...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/29205270/severe-multiple-sclerosis-reactivation-during-prolonged-lymphopenia-after-dimethyl-fumarate-discontinuation
#12
C Zecca, C G Antozzi, V Torri Clerici, M Ferrazzini, R E Mantegazza, S Rossi, C Gobbi
BACKGROUND: Delayed-release dimethyl fumarate (DMF) treatment can be associated with reduced lymphocyte and leucocyte counts, which might persist after DMF discontinuation. CASE PRESENTATION: We report the case of a patient with severe disease reactivation despite prolonged lymphopenia after DMF discontinuation. We describe the frequency and impact of prolonged lymphopenia after DMF discontinuation at two tertiary MS centres. A 36-year-old female patient with multiple sclerosis was switched to DMF after 14 years of treatment with interferon beta-1a...
December 3, 2017: Acta Neurologica Scandinavica
https://www.readbyqxmd.com/read/29198860/comparative-of-transcranial-magnetic-stimulation-and-other-treatments-in-experimental-autoimmune-encephalomyelitis
#13
Francisco J Medina-Fernandez, Begoña M Escribano, Evelio Luque, Javier Caballero-Villarraso, Jose L Gomez-Chaparro, Montserrat Feijoo, Fe I Garcia-Maceira, Alvaro Pacual-Leone, René Drucker-Colin, Isaac Tunez
The effects of transcranial magnetic stimulation (TMS), natalizumab (nata), dimethyl fumarate (DMF) and dexamethasone (DEX) on clinical score and oxidative stress produced by a single dose of myelin oligodendrocyte glycoprotein (MOG) in tail of Dark Agouti rats was studied. TMS (60Hz and 0.7 mT), nata (5mg/kg), DMF (15mg/kg) and DEX (300μg/kg) was applied for 21 after the administration of MOG (150μg). We estimated clinical score, as well as lipid peroxides, carbonylated proteins and reduced glutathione (GSH)/oxidized glutathione (GSSG) ratio content in brain, spinal cord and blood...
December 1, 2017: Brain Research Bulletin
https://www.readbyqxmd.com/read/29159204/immune-response-to-vaccines-is-maintained-in-patients-treated-with-dimethyl-fumarate
#14
Christian von Hehn, Jonathan Howard, Shifang Liu, Ven Meka, Joe Pultz, Devangi Mehta, Claudia Prada, Soma Ray, Michael R Edwards, Sarah I Sheikh
Objectives: To investigate the immune response to vaccinations in patients with relapsing forms of MS treated with delayed-release dimethyl fumarate (DMF) vs nonpegylated interferon (IFN). Methods: In this open-label, multicenter study, patients received 3 vaccinations: (1) tetanus-diphtheria toxoid (Td) to test T-cell-dependent recall response, (2) pneumococcal vaccine polyvalent to test T-cell-independent humoral response, and (3) meningococcal (groups A, C, W-135, and Y) oligosaccharide CRM197 conjugate to test T-cell-dependent neoantigen response...
January 2018: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/29141823/delayed-lymphocyte-re-population-following-discontinuation-of-dimethyl-fumarate-and-after-switching-to-other-disease-modifying-drug-therapies
#15
Bhupendra O Khatri, Sergey S Tarima, Benjamin Essig, Jean Sesing, Tayo Olapo
BACKGROUND: Dimethyl fumarate (DMF) reduces absolute lymphocyte counts, CD4, and CD8 counts, without significantly affecting total white blood cell counts. However, the recovery rate of these cells after discontinuation of DMF is unknown. The effect of subsequent disease modifying therapies (DMTs) on re-population rate is also unknown. OBJECTIVES: 1. To study the re-population rate of absolute lymphocytes, CD4, and CD8 counts back to baseline after discontinuation of DMF...
November 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29141809/treatment-satisfaction-across-injectable-infusion-and-oral-disease-modifying-therapies-for-multiple-sclerosis
#16
Tessa Eagle, Fiona Stuart, Alicia S Chua, Allison LaRussa, Kaitlynne Leclaire, Sandra L Cook, Tanuja Chitnis, Howard L Weiner, Bonnie I Glanz, Brian C Healy
BACKGROUND: The recent approval of oral disease-modifying therapies (DMTs) for multiple sclerosis (MS) has provided patients with a new route of therapy administration. Little research has compared patients' experiences with and perceptions of injectable, infusion and oral MS therapies. METHODS: Three hundred fifty-seven treated MS patients enrolled in the CLIMB study completed the Treatment Satisfaction Questionnaire for Medication (TSQM). The TSQM provides information regarding perceived effectiveness, side effects, convenience and overall satisfaction...
November 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29128972/persistence-with-dimethyl-fumarate-in-relapsing-remitting-multiple-sclerosis-a-population-based-cohort-study
#17
Irene Eriksson, Thomas Cars, Fredrik Piehl, Rickard E Malmström, Björn Wettermark, Mia von Euler
PURPOSE: To describe patients initiating dimethyl fumarate (DMF) and measure persistence with DMF, discontinuation, and switching in treatment-naïve DMF patients and patients switching to DMF from other multiple sclerosis disease-modifying treatments (DMTs). METHODS: A population-based cohort study of all Stockholm County residents initiating DMF from 9 May 2014 until 31 May 2017. All data were derived from a regional database that collects individual-level data on healthcare and drug utilization of all residents...
November 11, 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29124567/dimethyl-fumarate-modulates-oxidative-stress-and-inflammation-in-organs-after-sepsis-in-rats
#18
Amanda Della Giustina, Sandra Bonfante, Graciela Freitas Zarbato, Lucinéia Gainski Danielski, Khiany Mathias, Aloir Neri de Oliveira, Leandro Garbossa, Taise Cardoso, Maria Eduarda Fileti, Raquel Jaconi De Carli, Mariana Pereira Goldim, Tatiana Barichello, Fabricia Petronilho
Sepsis is defined as life-threatening organ dysfunction induced by a disrupted host response to infecting pathogens. Evidences suggest that oxidative stress is intrinsically related to sepsis progression. Dimethyl fumarate (DMF) is a novel oral therapeutic agent with anti-oxidant properties which exerts protective effects through activation of nuclear factor erythroid 2 (NFE2)-related factor 2 (Nrf2). Thus, the aim of this study is to evaluate the effect of DMF in different organs of rats submitted to an animal model of sepsis...
November 9, 2017: Inflammation
https://www.readbyqxmd.com/read/29121589/pharmacological-targeting-of-gsk-3-and-nrf2-provides-neuroprotection-in-a-preclinical-model-of-tauopathy
#19
Antonio Cuadrado, Sebastian Kügler, Isabel Lastres-Becker
Tauopathies are a group of neurodegenerative disorders where TAU protein is presented as aggregates or is abnormally phosphorylated, leading to alterations of axonal transport, neuronal death and neuroinflammation. Currently, there is no treatment to slow progression of these diseases. Here, we have investigated whether dimethyl fumarate (DMF), an inducer of the transcription factor NRF2, could mitigate tauopathy in a mouse model. The signaling pathways modulated by DMF were also studied in mouse embryonic fibroblast (MEFs) from wild type or KEAP1-deficient mice...
November 6, 2017: Redox Biology
https://www.readbyqxmd.com/read/29106333/monomethyl-fumarate-treatment-impairs-maturation-of-human-myeloid-dendritic-cells-and-their-ability-to-activate-t-cells
#20
Maria Antonietta Mazzola, Radhika Raheja, Keren Regev, Vanessa Beynon, Felipe von Glehn, Anu Paul, Isabelle Pierre, Pia Kivisakk, Howard L Weiner, Roopali Gandhi
BACKGROUND: Dimethyl fumarate (DMF) and its active metabolite monomethyl fumarate (MMF) effectively lead to reduction in disease relapses and active magnetic resonance imaging (MRI) lesions. DMF and MMF are known to be effective in modulating T- and B-cell responses; however, their effect on the phenotype and function of human myeloid dendritic cells (mDCs) is not fully understood. OBJECTIVE: To investigate the role of MMF on human mDCs maturation and function. METHODS: mDCs from healthy controls were isolated and cultured in vitro with MMF...
November 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
keyword
keyword
53593
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"